[{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Phoenix Tissue Repair"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Eidos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":2.8300000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":2.8300000000000001,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Bridgebio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Bridgebio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BBP-589","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Phoenix Tissue Repair"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Navire Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Navire Pharma","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Navire Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Infigratinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Calcilytix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Calcilytix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Calcilytix Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AAV5-gene therapy","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ BridgeBio","highestDevelopmentStatusID":"5","companyTruncated":"BridgeBio Pharma \/ BridgeBio"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BridgeBio Pharma \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio Pharma \/ Columbia University"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-954","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":2.4500000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2.4500000000000002,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Helsinn","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Helsinn"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ BridgeBio Pharma","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Fosdenopterin","moa":"Molybdenum cofactor synthesis","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachets","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-671","moa":"Glycolate oxidase","graph1":"Neurology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Venthera","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-681","moa":"PI3K","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"BridgeBio Pharma \/ Venthera","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Venthera"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"BBP-812","moa":"ASPA gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ORF-229","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Baylor College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio Pharma \/ Baylor College of Medicine"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutic","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutic","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutic"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-454","moa":"KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBP-418","moa":"Alpha-dystroglycan","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BBP-398","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.A.E","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ BridgeBio Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BridgeBio Pharma \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Qatar Investment Authority","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Qatar Investment Authority","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Qatar Investment Authority"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Resilience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"BBP-812","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ BridgeBio Pharma","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Blue Owl Capital","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Blue Owl Capital"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Invitae","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ BridgeBio Pharma","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio Pharma \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"BBO-8520","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Cormorant Asset Management"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Demerger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ BridgeBio Pharma","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BBP-812","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"BBP-631","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BridgeBio Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by BridgeBio Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BBP-418 (ribitol), an investigational oral substrate supplementation therapy, being investiated in patients with limb-girdle muscular dystrophy type 2I (LGMD2I/R9).

                          Brand Name : BBP-418

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Ribitol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 TKI in development for the treatment of achondroplasia in children.

                          Brand Name : Truseltiq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 17, 2024

                          Lead Product(s) : Infigratinib

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BBP-812 is an investigational intravenous adeno-associated virus serotype 9 (AAV9) gene therapy candidate which is currently being evaluated for the treatment of Canavan disease.

                          Brand Name : BBP-812

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : BBP-812

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BBP-631 is an investigational adeno-associated virus (AAV) 5 gene therapy candidate, which is being evaluated for the treatment of congenital adrenal hyperplasia.

                          Brand Name : BBP-631

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : BBP-631

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : GondolaBio will conduct R&D activities for early-stage clinical or preclinical programs across erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 21, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : GondolaBio

                          Deal Size : $300.0 million

                          Deal Type : Demerger

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BBP-418 (ribitol), an investigational oral substrate supplementation therapy, being investiated in patients with limb-girdle muscular dystrophy type 2I (LGMD2I/R9).

                          Brand Name : BBP-418

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 18, 2024

                          Lead Product(s) : Ribitol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.

                          Brand Name : BBO-8520

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 06, 2024

                          Lead Product(s) : BBO-8520,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 TKI in development for the treatment of achondroplasia in children.

                          Brand Name : Truseltiq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 04, 2024

                          Lead Product(s) : Infigratinib

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will support the clinical advancement of BBO-8520, which is being evaluated in early-stage clinical trials with pembrolizumab for treating KRASG12C mutated non-small cell lung cancer.

                          Brand Name : BBO-8520

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : BBO-8520,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Cormorant Asset Management

                          Deal Size : $200.0 million

                          Deal Type : Private Placement

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.

                          Brand Name : AG10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 04, 2024

                          Lead Product(s) : Acoramidis Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $250.0 million

                          Deal Type : Public Offering

                          blank